Anatomy of the FDA IND Application Process: 1,960 Submissions Annually, a Gateway to the Biopharma Pipeline
The Structure of the IND System and the 30-Day Automatic Review Mechanism
The Investigational New Drug (IND) application is a legally required document submitted to the FDA's CDER (Center for Drug Evaluation and Research) for a new drug candidate to enter human clinical trials. Upon receipt of an IND, the FDA conducts a safety review within 30 calendar days, and if no clinical hold is placed during this period, the IND is automatically approved. This '30-day automatic approval' mechanism is a core design principle of the U.S. IND system, serving as a mechanism to systematically ensure a balance between innovation speed and patient safety. Pre-IND meetings are scheduled approximately 60 days after the request, and the briefing package must be submitted 30 days before the meeting.
2024-2025 IND Submission Status and Pipeline Scale
According to official FDA CDER statistics, as of 2024, there are 14,870 active INDs (a 1.7% increase year-over-year), with 1,855 new submissions in the same year (1,139 for commercial use and 716 for research use). In 2025, a total of 1,960 submissions are expected, including 1,210 for commercial use and 750 for research use, representing an approximately 5.7% increase year-over-year. Over the five-year period from 2020 to 2024, the number of active INDs has grown from 12,935 to 14,870, a 15% increase, with the ratio of 65% for commercial use and 35% for research use remaining consistent. Rare diseases and oncology account for approximately 40% of active INDs.
New Trends in Biosimilars and Cell & Gene Therapies
The number of biosimilar INDs reached 90 active submissions in 2024 (a 7.1% year-over-year increase), marking the highest growth rate in four years. In 2026, the FDA will release a draft guidance expanding the scope of existing scientific evidence that can be used for IND submissions for cell and gene therapies for rare and serious diseases, reducing the barriers to entry for clinical trials for ultra-rare diseases. For example, Quantum BioPharma (QNTM) submitted a Phase 2 IND for its multiple sclerosis (MS) treatment candidate, Lucid-21-302 (Lucid-MS), in April 2026, but the FDA requested additional information and placed a clinical hold, demonstrating that automatic IND approval is not guaranteed.
From IND to New Drug Approval: Conversion Rate and Market Signals
Only approximately 12% of drugs that receive IND approval ultimately reach final FDA approval. Nevertheless, in 2025, the CDER approved 46 new drugs (34 NMEs and 12 biologics), of which 35% (16) were for oncology indications. The pipeline structure, with over 1,900 IND submissions annually and approximately 50 new drug approvals, numerically demonstrates the high failure rate of the biopharma sector, as well as the potential for significant value creation upon success.
With 1,960 IND submissions and 14,870 active INDs in 2025, the global biopharma pipeline's health can be gauged, and these figures are directly used to predict late-stage clinical and NDA submissions in the following 2-3 years. The 65% share of commercial INDs suggests that corporate R&D investment remains strong, and the structure in which rare diseases and oncology account for 40% of active INDs supports the continued growth in demand for CROs (contract research organizations) and CDMOs (contract development and manufacturing organizations) in these areas. The reality that the conversion rate from IND to final approval is approximately 12%, and the average time required is 10-15 years, makes this a key variable in setting the discount rate when evaluating the value of early-stage pipeline assets (risk-adjusted NPV), and investors should closely monitor whether the IND is automatically approved or a clinical hold is placed (as in the Quantum BioPharma/Lucid-MS case) as a pipeline risk signal.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application